Articoli con mandati relativi all'accesso pubblico - Andrew W RobertsUlteriori informazioni
Non disponibili pubblicamente: 17
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
AJ Souers, JD Leverson, ER Boghaert, SL Ackler, ND Catron, J Chen, ...
Nature medicine 19 (2), 202-208, 2013
Mandati: National Health and Medical Research Council, Australia
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
A Kotschy, Z Szlavik, J Murray, J Davidson, AL Maragno, ...
Nature 538 (7626), 477-482, 2016
Mandati: National Health and Medical Research Council, Australia
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
S Stilgenbauer, B Eichhorst, J Schetelig, S Coutre, JF Seymour, T Munir, ...
The lancet oncology 17 (6), 768-778, 2016
Mandati: US National Institutes of Health
Targeting GM-CSF in inflammatory diseases
IP Wicks, AW Roberts
Nature Reviews Rheumatology 12 (1), 37-48, 2016
Mandati: National Health and Medical Research Council, Australia
Dynamic molecular monitoring reveals that SWI–SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma
R Agarwal, YC Chan, CS Tam, T Hunter, D Vassiliadis, CE Teh, ...
Nature Medicine 25 (1), 119-129, 2019
Mandati: Swiss National Science Foundation, Howard Hughes Medical Institute, National …
Chemotherapy and venetoclax in elderly acute myeloid leukemia trial (CAVEAT): a phase Ib dose-escalation study of venetoclax combined with modified intensive chemotherapy
CC Chua, AW Roberts, J Reynolds, CY Fong, SB Ting, JM Salmon, ...
Journal of Clinical Oncology 38 (30), 3506-3517, 2020
Mandati: National Health and Medical Research Council, Australia, Medical Research …
Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1
TC Teh, NY Nguyen, DM Moujalled, D Segal, G Pomilio, S Rijal, ...
Leukemia 32 (2), 303-312, 2018
Mandati: National Health and Medical Research Council, Australia
Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC
SJ Busfield, M Biondo, M Wong, HS Ramshaw, EM Lee, S Ghosh, ...
Leukemia 28 (11), 2213-2221, 2014
Mandati: National Health and Medical Research Council, Australia, Blood Cancer UK
Targeting BCL-2-like proteins to kill cancer cells
S Cory, AW Roberts, PM Colman, JM Adams
Trends in cancer 2 (8), 443-460, 2016
Mandati: National Health and Medical Research Council, Australia
Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199
SL Khaw, D Merino, MA Anderson, SP Glaser, P Bouillet, AW Roberts, ...
Leukemia 28 (6), 1207-1215, 2014
Mandati: Australian Research Council, National Health and Medical Research Council …
Neutrophils require SHP1 to regulate IL-1β production and prevent inflammatory skin disease
BA Croker, RS Lewis, JJ Babon, JD Mintern, DE Jenne, D Metcalf, ...
The Journal of Immunology 186 (2), 1131-1139, 2011
Mandati: US National Institutes of Health
BET inhibition represses miR17-92 to drive BIM-initiated apoptosis of normal and transformed hematopoietic cells
Z Xu, PP Sharp, Y Yao, D Segal, CH Ang, SL Khaw, BJ Aubrey, J Gong, ...
Leukemia 30 (7), 1531-1541, 2016
Mandati: National Health and Medical Research Council, Australia
Low adhesion receptor levels on circulating platelets in patients with lymphoproliferative diseases before receiving Navitoclax (ABT-263)
J Qiao, SM Schoenwaelder, KD Mason, H Tran, AK Davis, ZS Kaplan, ...
Blood, The Journal of the American Society of Hematology 121 (8), 1479-1481, 2013
Mandati: National Health and Medical Research Council, Australia
Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma
MA Dengler, CE Teh, R Thijssen, L Gangoda, P Lan, MJ Herold, DH Gray, ...
Oncogene 39 (9), 2009-2023, 2020
Mandati: National Health and Medical Research Council, Australia
Granulocyte colony-stimulating factor
AW Roberts, NA Nicola
Colony-stimulating factors, 203-226, 2020
Mandati: US National Institutes of Health
Towards a four-dimensional view of neutrophils
BA Croker, AW Roberts, NA Nicola
Leucocytes: Methods and Protocols, 87-99, 2011
Mandati: US National Institutes of Health
Targeting apoptotic pathways to treat lymphoid malignancies
AW Roberts
Rinsho Ketsueki 57 (10), 2054-2058, 2016
Mandati: National Health and Medical Research Council, Australia
Disponibili pubblicamente: 99
Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia
AW Roberts, MS Davids, JM Pagel, BS Kahl, SD Puvvada, JF Gerecitano, ...
New England Journal of Medicine 374 (4), 311-322, 2016
Mandati: US National Institutes of Health
Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease
AW Roberts, JF Seymour, JR Brown, WG Wierda, TJ Kipps, SL Khaw, ...
Journal of Clinical Oncology 30 (5), 488-496, 2012
Mandati: US National Institutes of Health
The genomic landscape of hypodiploid acute lymphoblastic leukemia
L Holmfeldt, L Wei, E Diaz-Flores, M Walsh, J Zhang, L Ding, ...
Nature genetics 45 (3), 242-252, 2013
Mandati: US National Institutes of Health, Swedish Research Council
Le informazioni sulla pubblicazione e sul finanziamento vengono stabilite automaticamente da un software